

<b>Product Name</b>	: MRE-269
<b>Synonyms</b>	: MRE-269; MRE269; MRE 269; ACT-333679
<b>Cat No.</b>	: M17517
<b>CAS Number</b>	: 475085-57-5
<b>Molecular Formula</b>	: C <sub>25</sub> H <sub>29</sub> N <sub>3</sub> O <sub>3</sub>
<b>Formula Weight</b>	: 419.52
<b>Chemical Name</b>	: 2-(4-((5,6-diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)acetic acid
<b>Description</b>	MRE-269, also known as ACT-333679, is a long-acting and highly selective prostacyclin receptor agonist. MRE-269, the active form or metabolite of Selexipag (NS-304), is much more selective for the IP receptor than are the prostacyclin analogs beraprost and iloprost, which also have high affinity for the EP(3) receptor.
<b>Pathway</b>	: Others
<b>Target</b>	: Other Targets
<b>Receptor</b>	: HIV-1 protease
<b>Solubility</b>	: DMSO : ≥ 50 mg/mL. 119.18 mM; H <sub>2</sub> O : < 0.1 mg/mL
<b>SMILES</b>	: CC1CCC2(CCC3(C(=CCC4C3(CCC5C4(CCC(=O)C5(C)C)C)C)C2C1C)C)C(=O)O
<b>Storage</b>	: (-20°C)
<b>Stability</b>	: ≥ 2 years
<b>Reference</b>	:

